Renal and hormonal effects and tolerance of an ANP analogue in healthy man.
The effect of an analogue of atrial natriuretic peptide (P-ANP) on glomerular filtration rate (GFR), renal plasma flow (RPF), urinary flow rate, urinary sodium excretion, tubular function estimated by the lithium clearance technique, and plasma levels of sodium and water homeostatic hormones, has been studied in 40 healthy males. Placebo or P-ANP 0.3, 1.5, or 3.0 micrograms.kg-1 bwt were given as an intravenous bolus injection to different groups. P-ANP did not cause any immediate change in GFR or RPF, but significant dose-dependent increases in filtration fraction, urinary flow rate and urinary excretion rate of sodium were detected during the first 30 min after administration. Proximal absolute and fractional tubular reabsorption and distal absolute tubular reabsorption of sodium did not change after injection of P-ANP, while the distal fractional reabsorption of sodium was reduced in a dose dependent manner during the first 30 min. Plasma angiotensin II and aldosterone were significantly increased 30 and 150 min after dosage, whereas plasma atrial natriuretic peptide, plasma arginine vasopressin, and urinary excretion of prostaglandin E2 were unchanged. Cyclic guanosine monophosphate both in plasma and urine were increased in a dose-dependent manner. P-ANP cause a significant reduction in diastolic blood pressure and an increase in pulse rate. Two subjects had vasovagal syncope 30-60 min after injection of P-ANP. It is concluded that P-ANP has natriuretic, diuretic and hypotensive properties in healthy man.
Eiskjaer
H
H
Department of Medicine and Nephrology C, Skejby Hospital, University Hospital Aarhus, Denmark.
Schmiegelow
M
M
Jespersen
B
B
Tietze
I N
IN
Jensen
J D
JD
Sørensen
S S
SS
Thomsen
K
K
Pedersen
E B
EB
D000328:Adult; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000097:blood; D001127:Arginine Vasopressin / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004361:Drug Tolerance; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006728:Hormones / Q000097:blood*; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D011188:Potassium / Q000652:urine; D011674:Pulse / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects*; D012964:Sodium / Q000652:urine; D014554:Urination / Q000187:drug effects*
D006728:Hormones; D010446:Peptide Fragments; D000804:Angiotensin II; D001127:Arginine Vasopressin; C074733:ANF (4-28), Leu(8,18)-Ile(12)-Ala(20)-MePhe(26)-Tyr(28)-Pro(29)-; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012964:Sodium; D011188:Potassium